XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flows from operating activities    
Net loss $ (229,864) $ (111,894)
Adjustments to reconcile net loss to net cash used in operating activities    
Loss from Continuation Advances   52,000
Depreciation 6,937 4,943
Amortization of intangible assets 685 154
Amortization of right-of-use assets 5,152 2,403
Amortization of debt discount and financing costs 480 381
Stock-based compensation 60,658 54,417
Amortization from investment premium 1,069 3,107
Deferred income taxes   (94,824)
Change in the estimated fair value of contingent consideration (2,221)  
Loss on disposition of equipment 82  
Changes in assets and liabilities    
Accounts receivable 1,485 (6,871)
Inventory (20,700) (5,453)
Prepaid expenses and other assets (5,685) (1)
Accounts payable 1,511 196
Accrued expenses (11,054) 10,267
Deferred revenue (3,575) 17,930
Operating lease liabilities (5,905) (3,231)
Other liabilities (1,700) (2,996)
Net cash used in operating activities (202,645) (79,472)
Cash flows from investing activities    
Purchase of property and equipment (11,846) (3,089)
Purchase of investments (307,899) (857,421)
Sales of investments   212,734
Maturities of investments 355,425 223,285
Net cash provided by (used) in investing activities 35,680 (744,284)
Cash flows from financing activities    
Continuation Advances   (52,000)
Proceeds from issuance of Convertible Senior Notes, net of issuance costs   895,536
Proceeds from issuance of common stock under equity offerings, net of issuance costs   294,846
Proceeds from issuance of common stock from equity plans 9,983 30,121
Notes payable principal payoff (1,180)  
Other   (246)
Net cash provided by financing activities 8,803 1,168,257
Net (decrease) increase in cash and cash equivalents and restricted cash (158,162) 344,501
Cash and cash equivalents and restricted cash at beginning of period 465,817 85,947
Cash and cash equivalents and restricted cash at end of period 307,655 430,448
Cash and cash equivalents at end of period 304,433 425,388
Restricted cash at end of period $ 3,222 5,060
Supplemental disclosure of non-cash investing and financing activities    
Issuance of common stock in acquisition of Omniome   237,884
Circulomics, Inc [Member]    
Cash flows from investing activities    
Cash paid for purchase of business acquisition, net of cash acquired   (28,560)
Omniome, Inc [Member]    
Cash flows from investing activities    
Cash paid for purchase of business acquisition, net of cash acquired   $ (291,233)